Clinical trials: Nausea With Vomiting Chemotherapy-Induced
Lung Neoplasms
The Effect and Mechanism of Electroacupuncture on Acute Chemotherapy-induced Nausea and Vomiting
The purpose of this study is to compare the preventive effect of electroacupuncture and sham acupuncture on acute chemotherapy-induced nausea and vomiting and then investigate its potential mechanism by using functional Magnetic…
- Trial name
- NCT02469493
- Testing
- acupuncture (Huatuo)
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Xidian University
Nausea, Vomiting
A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)
This is an efficacy and safety study to compare aprepitant with ondansetron for the prevention of nausea and vomiting in the first cycle of moderately emetogenic chemotherapy (MEC) in participants with solid tumors.
- Trial name
- KMEC (NCT01636947)
- Testing
- Aprepitant, Ondansetron, Dexamethasone
- Volunteers
- 494 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting
Granisetron Transdermal Patch System for Prevention of CINV by CapeOX
This study aims to explore the prevention of delayed chemotherapy induced by CAPOX regimen with granisetron transdermal patch。
- Trial name
- NCT05325190
- Testing
- Granisetron Transdermal Patch System
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Chemotherapy Induced Nausea and Vomiting
Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy
The purpose of this study is to determine the feasibility of a larger trial comparing olanzapine and aprepitant and to obtain preliminary data on the effectiveness of these two medications to treat nausea and vomiting in children…
- Trial name
- NCT02097823
- Testing
- Olanzapine, Aprepitant
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Indiana University
Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)
This study is designed to assess the safety and efficacy of palonesetron in preventing chemotherapy-induced nausea and vomiting (CINV) when administered to participants who have experienced either vomiting and or at least…
- Trial name
- NCT01054456
- Testing
- palonesetron
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Eisai Inc.
Oncology, Breast Cancer
Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy
This study explores whether a commonly used medication called Pantoprazole can help prevent delayed nausea and vomiting from chemotherapy for early breast cancer.
- Conditions
- Oncology, Breast Cancer, Chemotherapy-induced Nausea and Vomiting
- Trial name
- PantoCIN (NCT03948477)
- Testing
- Pantoprazole 40mg
- Where
- 10 sites in New Zealand
- Volunteers
- 160 people
- Sponsor
- University of Auckland, New Zealand
Chemotherapy-induced Nausea and Vomiting
Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients
In this study, patients will receive ondansetron 8mg and dexamethasone 10mg intravenously 30 minutes prior to myeloablative preparative chemotherapy until the last day of chemotherapy.
- Trial name
- NCT01370408
- Testing
- Palonosetron, ondansetron, Dexamethasone
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Northside Hospital, Inc.
Breast Cancer
Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile
The objectives of this study are to determine if pharmacogenetic (PG) analysis of an individual enable optimal selection of antiemetic regimen for patients undergoing the first cycle of AC (Adriamycin + Cyclophosphamide) or FEC…
- Trial name
- NCT07455955
- Testing
- Standard antiemetic regimen or Olanzapine antiemetic regimen
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong
Nausea and Vomiting Chemotherapy-Induced
Medical Cannabis Observational Study for Antiemetic Intervention in Chemotherapy
The goal of this observational study is to evaluate the associations between patient-directed medical cannabis use and chemotherapy-induced nausea and vomiting (CINV), as well as other treatment-related symptoms, among patients…
- Trial name
- MOSAIC (NCT07374939)
- Testing
- Medical Cannabis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Rochester
Stomach Cancer, Chemotherapy-induced Nausea and Vomiting
The Effect of Stress Ball on Nausea, Anxiety, and Fatigue in Patients With Stomach Cancer
In this study, we will observe the effects of the Stress Ball.
- Conditions
- Stomach Cancer, Chemotherapy-induced Nausea and Vomiting, Fatigue
- Trial name
- NCT07540169
- Testing
- A device/tool called a stress ball
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 52 people
- Sponsor
- Yuzuncu Yil University
Nausea, Vomiting
Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
The purpose of this study is to determine the efficacy and tolerability of an investigational drug for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.
- Conditions
- Nausea, Vomiting, Breast Neoplasms
- Trial name
- NCT00092196
- Testing
- MK0869, aprepitant / Duration of Treatment: 3 days
- Volunteers
- 820 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastrointestinal Neoplasms, Chemotherapy-induced Nausea and Vomiting
Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy
The purpose of this study is to study whether adding Aprepitant to Palonosetron and dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by FOLFIRI or FOLFOX chemotherapy regimen among…
- Trial name
- CINV (NCT03674294)
- Testing
- Aprepitant, Palonosetron, Dexamethasone
- Where
- China
- Volunteers
- 248 people
- Sponsor
- Sun Yat-sen University
Pain, Nausea With Vomiting Chemotherapy-Induced
The Effect of Acupressure on Pain, Nausea-Vomiting, and Mental Well-Being in Oncology Patients
The goal of this clinical trial is to compare the effect of self acupressure and acupressure applied by therapists on pain, nausea-vomiting, and mental well-being in oncology patients.
- Conditions
- Pain, Nausea With Vomiting Chemotherapy-Induced, Mental Health Wellness 1
- Trial name
- NCT05898880
- Testing
- Self-acupressure, Acupressure by therapists, Control group
- Where
- Turkey (Türkiye)
- Volunteers
- 96 people
- Sponsor
- Mersin University
Chemotherapy-induced Nausea and Vomiting
Anti-emetic Prophylaxis With or Without Dexamethasone
To evaluate the efficacy and safety of a fosaprepitant, tropisetron, and olanzapine antiemetic regimen, with or without dexamethasone, in patients receiving highly emetogenic chemotherapy with epirubicin and cyclophosphamide.
- Trial name
- NCT05242874
- Testing
- Fosaprepitant, tropisetron, and olanzapine-based antiemetic regimen, Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen
- Where
- 2 sites in China
- Volunteers
- 442 people
- Sponsor
- Henan Cancer Hospital
Malignant Solid Tumors, Moderate to High Emetogenic Chemotherapy (MEC/HEC) Drugs
Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting
The goal of this clinical trial is to learn if medroxyprogesterone acetate oral suspension (Meishiya®) works to prevent nausea and vomiting caused by single-day moderate to high emetogenic chemotherapy (MEC/HEC) in the…
- Trial name
- NCT07124195
- Testing
- Medroxyprogesterone acetate oral suspension, high antiemetic regimen, moderate antiemetic regimen
- Where
- China
- Volunteers
- 126 people
- Sponsor
- The First Affiliated Hospital of Xinxiang Medical College
Chemotherapy-induced Nausea and Vomiting
Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting
To compare the antiemetic combination of palonosetron, dexamethasone, and aprepitant (PDA) with antiemetic combination of palonosetron and dexamethasone (PD) in nasopharyngeal carcinoma patients receiving docetaxel, cisplatin…
- Trial name
- CINV (NCT02933099)
- Testing
- Aprepitant+palonosetron+dexamethasone, palonosetron+dexamethasone
- Volunteers
- 300 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Chemotherapy-induced Nausea and Vomiting
NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer
This study evaluates if the activity of one-day of NEPA plus dexamethasone, to prevent chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant AC-based chemotherapy, is maintained during all the…
- Trial name
- GIM15-NEPA (NCT03862144)
- Testing
- Netupitant/Palonosetron
- Volunteers
- 150 people
- Sponsor
- Consorzio Oncotech
Chemotherapy-Induced Nausea and Vomiting
Observational Study on the Use of Akynzeo® in Patients Receiving HEC
This Canadian, multi-centre, prospective, observational real-world study is designed to collect patient-reported outcome data on the use of Akynzeo® (netupitant/palonosetron) for the prevention of nausea and vomiting in oncology…
- Trial name
- EVOLVE_CINV (NCT03649230)
- Testing
- 300mg netupitant/0.5mg palonosetron hydrochloride
- Where
- 17 sites in Canada
- Volunteers
- 207 people
- Sponsor
- Purdue Pharma, Canada
Chemotherapy-Induced Nausea and Vomiting, Ovarian Cancer
Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin
The current recommended guideline for patients receiving moderately emetogenic chemotherapy (MEC) is the combination of a 5-HT3 receptor antagonist and corticosteroid.
- Trial name
- NCT01012336
- Testing
- Aprepitant/Ramosetron/Dexamethasone
- Where
- South Korea
- Volunteers
- 89 people
- Sponsor
- Samsung Medical Center
Nausea and Vomiting, Postoperative, Nausea With Vomiting Chemotherapy-Induced
Crossover Study Comparing Ondansetron Orally Dissolving Film Strip (ODFS) With Zofran Orally Disintegrating Tablets
This was an open-label, balanced, two-treatment, two-period, randomized sequence crossover bioequivalence study with a 7-day washout between periods. Each treatment was administered after an overnight (10 hours) fast.
- Trial name
- 01905/08-09 (NCT01217190)
- Testing
- Ondansetron (ODFS), Zofran (ODT)
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- MonoSol Rx